|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.620 USD | -6.76% |
|
+3.56% | +11.49% |
| Capitalization | 135.37Cr 116.61Cr 108.67Cr 101.1Cr 188.08Cr 12TCr 201.75Cr 1.25TCr 491.31Cr 5.85TCr 507.61Cr 497.23Cr 21TCr | P/E ratio 2025 * |
-15.1x | P/E ratio 2026 * | -103x |
|---|---|---|---|---|---|
| Enterprise value | 119.39Cr 102.84Cr 96Cr 89Cr 165.88Cr 11TCr 177.94Cr 1.1TCr 433.32Cr 5.16TCr 447.69Cr 438.53Cr 19TCr | EV / Sales 2025 * |
0.63x | EV / Sales 2026 * | 0.43x |
| Free-Float |
75.33% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Clover Health Investments, Corp.
| 1 day | -6.76% | ||
| 1 week | +3.56% | ||
| Current month | +11.49% | ||
| 3 months | -6.43% | ||
| 6 months | -12.08% | ||
| Current year | +11.49% |
| 1 week | 2.51 |  | 2.88 |
| 1 month | 2.31 | | 2.88 |
| Current year | 2.35 | | 2.88 |
| 1 year | 2.12 | | 4.87 |
| 3 years | 0.61 | | 4.87 |
| 5 years | 0.61 | | 28.85 |
| 10 years | 0.61 | | 28.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Andrew Toy
CEO | Chief Executive Officer | 47 | 01/01/2023 |
Peter Kuipers
DFI | Director of Finance/CFO | 54 | 07/05/2024 |
Conrad Wai
CTO | Chief Tech/Sci/R&D Officer | 45 | 28/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Vivek Garipalli
CHM | Chairman | 47 | 01/01/2023 |
Andrew Toy
BRD | Director/Board Member | 47 | 01/11/2018 |
William Robinson
BRD | Director/Board Member | 61 | 25/03/2021 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +5.08% | 0.02% | 324 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -6.76% | +3.56% | -34.17% | +111.29% | 135.37Cr | |
| +1.19% | -2.27% | -37.62% | -30.76% | 31TCr | |
| +2.44% | +1.91% | -1.89% | -20.93% | 8.49TCr | |
| +2.56% | -2.10% | -2.33% | -11.54% | 7.42TCr | |
| +3.58% | +2.30% | +1.60% | -42.21% | 3.42TCr | |
| +2.38% | +0.75% | -25.15% | -38.64% | 2.32TCr | |
| +2.57% | +5.58% | -32.77% | -35.47% | 995.82Cr | |
| +3.47% | +7.40% | +61.87% | +79.14% | 450.21Cr | |
| Average | +0.84% | +2.14% | -8.81% | +1.36% | 6.74TCr | |
| Weighted average by Cap. | +1.08% | -0.93% | -23.19% | -26.45% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 190.37Cr 163.98Cr 152.82Cr 142.17Cr 264.49Cr 17TCr 283.72Cr 1.76TCr 690.91Cr 8.22TCr 713.83Cr 699.23Cr 30TCr | 262.17Cr 225.83Cr 210.46Cr 195.79Cr 364.25Cr 24TCr 390.74Cr 2.42TCr 951.51Cr 11TCr 983.08Cr 962.97Cr 42TCr |
| Net income | -8.85Cr -7.62Cr -7.1Cr -6.61Cr -12Cr -799.4Cr -13Cr -82Cr -32Cr -382.16Cr -33Cr -32Cr -1.4TCr | -1.25Cr -1.08Cr -1.01Cr -93.57L -1.74Cr -113.2Cr -1.87Cr -12Cr -4.55Cr -54Cr -4.7Cr -4.6Cr -198.53Cr |
| Net Debt | -16Cr -14Cr -13Cr -12Cr -22Cr -1.44TCr -24Cr -147.38Cr -58Cr -690.18Cr -60Cr -59Cr -2.53TCr | -23Cr -20Cr -19Cr -17Cr -32Cr -2.11TCr -35Cr -215.49Cr -85Cr -1.01TCr -88Cr -86Cr -3.7TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | 2.620 $ | -6.76% | 69,96,719 |
| 14/26/14 | 2.810 $ | +10.63% | 1,32,23,716 |
| 13/26/13 | 2.540 $ | -3.79% | 46,90,470 |
| 12/26/12 | 2.640 $ | +1.54% | 35,44,837 |
| 09/26/09 | 2.600 $ | +2.77% | 42,03,296 |
Delayed Quote Nasdaq, January 16, 2026 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CLOV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition